Keshaav Bagri

Thank you for the opportunity to ask questions. I have two points I would like to raise. First, regarding the export data, we noticed a resurgence in volumes for xanomeline and Bempedoic acid. Could you provide some color on whether the demand for these molecules has indeed picked up meaningfully? And if we expect this trend to continue in the subsequent quarter?

The last question would be on the topic of EBITDA margins. Like in a previous conference call, you had highlighted that FY24 was an exceptional year for margins, driven by multiple factors aligning simultaneously, t he lower raw material costs, stronger TDM over sales and other contributing elements. You also noted that replicating those margins would require similar conditions to converge.